Dharmendra Kumar1, Sharad Srivastava1, M S Tevatia2, Kanwaljit Kaur3, Amit Sood4, Manish Manrai5, Reema Mukerjee6. 1. Senior Advisor (Medicine) & Gastroenterologist, Medical Division, Command Hospital (SC), Pune, India. 2. Consultant (Pathology), Command Hospital (SC), Pune, India. 3. Classified Specialist (Pathology), Base Hospital Barrackpore, Kolkata, India. 4. Classified Specialist (Pediatrics), Command Hospital (WC), Chandimandir, India. 5. Associate Professor, Dept of Internal Medicine, Armed Forces Medical College, Pune, India. 6. Professor, Dept of Community Medicine, Armed Forces Medical College, Pune, India.
Abstract
BACKGROUND: Childhood immunization against hepatitis B is one of the most effective strategies for reducing the global burden of chronic hepatitis B infection and its sequelae. There are limited data from India on both the anti-Hep B antibody titres in children after vaccination and the age-related decline in the titres. This study was planned to estimate the proportion of children in the age group of 1-10 years who develop protective levels of anti-hepatitis B antibodies after childhood vaccination and to examine the change in antibody titres with age in these children. METHODS: A hospital-based cross-sectional study was carried out in children admitted to the hospital for various ailments. Basic demographic data, vaccination history and HBsAg status of the mother were recorded. All the enrolled children were evaluated for HBsAg and anti hepatitis B surface antibody (anti-HBS) titres. Institutional ethical clearance was obtained, and informed consent from the parents of the children was taken before drawing samples. RESULTS: We found that 68.86% Confidence Interval ((CI): 59.8-76.8%) of the children showed protective antibody titres after vaccination, while 31.14% (CI: 23.1-40.2%) of the children had titres less than 10 IU/L. Although 100% of children in the age group from birth to three years had titres more than 10 IU/L, this percentage showed a decline across the age groups, and 60% of children aged 9-10 years had titres less than 10 IU/L. CONCLUSION: Childhood vaccination against hepatitis B is effective in 68% children, and the antibody levels showed a steady decline with increasing age.
BACKGROUND: Childhood immunization against hepatitis B is one of the most effective strategies for reducing the global burden of chronic hepatitis B infection and its sequelae. There are limited data from India on both the anti-Hep B antibody titres in children after vaccination and the age-related decline in the titres. This study was planned to estimate the proportion of children in the age group of 1-10 years who develop protective levels of anti-hepatitis B antibodies after childhood vaccination and to examine the change in antibody titres with age in these children. METHODS: A hospital-based cross-sectional study was carried out in children admitted to the hospital for various ailments. Basic demographic data, vaccination history and HBsAg status of the mother were recorded. All the enrolled children were evaluated for HBsAg and anti hepatitis B surface antibody (anti-HBS) titres. Institutional ethical clearance was obtained, and informed consent from the parents of the children was taken before drawing samples. RESULTS: We found that 68.86% Confidence Interval ((CI): 59.8-76.8%) of the children showed protective antibody titres after vaccination, while 31.14% (CI: 23.1-40.2%) of the children had titres less than 10 IU/L. Although 100% of children in the age group from birth to three years had titres more than 10 IU/L, this percentage showed a decline across the age groups, and 60% of children aged 9-10 years had titres less than 10 IU/L. CONCLUSION: Childhood vaccination against hepatitis B is effective in 68% children, and the antibody levels showed a steady decline with increasing age.
Authors: Kamilla Vêncio Frauzino Alexandre; Regina Maria Bringel Martins; Márcia Maria de Souza; Isolina Maria Xavier Rodrigues; Sheila Araujo Teles Journal: Mem Inst Oswaldo Cruz Date: 2012-12 Impact factor: 2.743
Authors: Thomas John Bender; Umid Sharapov; Okey Utah; Jian Xing; Dale Hu; Jolanta Rybczynska; Jan Drobeniuc; Saleem Kamili; Philip R Spradling; Anne C Moorman Journal: Vaccine Date: 2013-12-23 Impact factor: 3.641